Der Hautarzt

, Volume 56, Issue 9, pp 819–830

Etanercept

Ein effektiver TNF-α-Antagonist zur Behandlung von Psoriasisarthritis und Psoriasis vulgaris
Leitthema

Zusammenfassung

Mit dem TNF-α-Antagonisten Etanercept steht zur Behandlung der Psoriasisarthritis und der Psoriasis vulgaris ein effektives Medikament zur Verfügung. Etanercept ist ein rekombinant hergestelltes Fusionsprotein, das aus 2 Domänen des p-75-TNF-α-Rezeptors und dem Fc-Fragment des humanen IgG1 besteht. Als Protein ist Etanercept zwingend parenteral (subkutan) zu applizieren. Die Wirksamkeit ist sowohl für die psoriatischen Hautläsionen als auch die Gelenkbeteiligung durch kontrollierte Studien belegt. Die Dosierung beträgt 2-mal 25 mg/Woche, bei schweren Fällen ist eine Dosiserhöhung auf 2-mal 50 mg/Woche möglich. Vor Behandlungsbeginn sind Infektionen einschließlich Tuberkulose auszuschließen. Eine Kombinationsbehandlung mit anderen immunsuppressiven Medikamenten bzw. pharmakologischen Immunmodulatoren ist möglich. Alle topischen Antipsoriatika können ebenfalls mit einer Etanercepttherapie kombiniert werden. Im sog. Off-label-Gebrauch wurde das Fusionsprotein bei einer Reihe weiterer, überwiegend entzündlicher Dermatosen mit Erfolg eingesetzt. Bei richtiger Indikationsstellung, regelrechtem Monitoring und Beobachtung möglicher unerwünschter Wirkungen hat Etanercept ein akzeptables Sicherheitsprofil. Etanercept stellt neben anderen Biologics eine der wichtigsten therapeutischen Innovationen der letzten Jahre dar.

Schlüsselwörter

Etanercept (Enbrel®Klinischer Einsatz Psoriasis vulgaris Psoriasisarthritis TNF-α 

Abkürzungen

ACR

American College of Rheumatology

AE

Adverse Event

ANA

Antinukleäre Antikörper

CD

Clusters of differentiation (Nomenklatur der Oberflächenmarker)

DLQI

Dermatology Life Quality Index (Index für Erfassung der Lebensqualität)

FDA

Food and Drug Administration (US-amerikanische Zulassungsbehörde)

GCP

Good Clinical Practice

HAQ

Health Assessment Questionnaire

MTX

Methotrexat

NSAR

Nichtsteroidale Antirheumatika

PASI

Psoriasis Area and Severity Index

PGA

Physician Global Assessment

PsARC

Psoriasis Arthritis Response Criteria

RA

Rheumatoide Arthritis

TNF-α

Tumornekrosefaktor-α

UAW

Unerwünschte Arzneimittelwirkungen

VAS

Visual Analog Scala (Visuelle Analogskala)

Etanercept

An effective TNF α-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis

Abstract

Etanercept, an inhibitor of TNF α, has been found effective in the treatment of psoriatic arthritis and psoriasis vulgaris. Etanercept is a fusion protein made up of domains of the soluble, fully human p75-TNF α receptor and the Fc portion of human IgG1. The drug is a protein which must be administered subcutaneously. Several controlled studies have highlighted its efficacy for both skin symptoms and joint involvement. The usual dose is 25 mg s.c. twice weekly. Higher dosages of 50 mg twice weekly may be used in severe cases. Before starting the therapy with etanercept, infections including tuberculosis have to be excluded. Methotrexate and other pharmacological immunosuppressive agents can be combined with etanercept, as can all standard topical agents. Etanercept in off-label use has been found to also be useful in several other inflammatory dermatologic conditions. If patients are carefully monitored, etanercept is generally well-tolerated and has a good safety profile. The development of novel biologic agents such as etanercept is one of the most important therapeutic innovations of recent years.

Keywords

Etanercept (Enbrel®Clinical use Chronic plaque psoriasis Psoriatic arthritis TNF-α 

Literatur

  1. 1.
    Blumberg BS, Bunim JJ, Calkins E et al. (1964) ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 7:93–97Google Scholar
  2. 2.
    Bruce IN (2003) Psoriatic arthritis: clinical features. In: Hochberg MC, Silman AJ, Smolen JS et al. (eds) Rheumatology, 3rd edn. Elsevier, London, pp 1241–1252Google Scholar
  3. 3.
    Chambers C, Johnson D, Jones KL (2005) Safety of anti-TNF-α medications in pregnancy. J Am Acad Dermatol [Suppl] 52:196Google Scholar
  4. 4.
    Clegg DO, Reda DJ, Mejias E et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriasic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39:2013–2020PubMedGoogle Scholar
  5. 5.
    Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493–2537PubMedGoogle Scholar
  6. 6.
    AHFS Drug information (2003) Etanercept. American Society of Health-System Pharmacists, Bethesda, pp 3607–3613Google Scholar
  7. 7.
    Goffe B, Cather JC (2003) Etanercept: an overview. J Am Acad Dermatol 49:S105–S111CrossRefPubMedGoogle Scholar
  8. 8.
    Gottlieb AB, Metheson RT, Lowe N et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627–1632CrossRefPubMedGoogle Scholar
  9. 9.
    Gottlieb AB, Gordon K, Wang A, Zitnik R (2004) Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response. J Am Acad Dermatol 50:P146CrossRefGoogle Scholar
  10. 10.
    Gottlieb AB (2003) Etanercept for treatment of psoriasis and psoriatic arthritis. In: Weinstein GD, Gottlieb AB (eds) Therapy of moderate-to-severe psoriasis, 2nd edn. Dekker, New York Basel, pp 261–283Google Scholar
  11. 11.
    Holman J, Gardiner M, Wallis WJ et al. (2003) Tuberculosis reports with etanercept (Enbrel) therapy. Ann Rheum Dis 61 [Suppl 1]:167Google Scholar
  12. 12.
    Iyer S, Yamauchi P, Lowe NJ (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118–121CrossRefPubMedGoogle Scholar
  13. 13.
    Klareskog L, Moreland LM, Cohen SB et al. (2001) Global safety and efficacy of upto five years of etanercept (Enbrel) therapy. Arthritis Rheum 44 [Suppl]:S77 (Abstract 150)Google Scholar
  14. 14.
    Kohno T, Stevens S, Louie J, Amgen Inc.,Thousand Oaks, CA, United States (2005) Adalimumab and infliximab bind to Fc-Receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. J Am Acad Dermatol 52 [Suppl]:36Google Scholar
  15. 15.
    Leonardi CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014–2022CrossRefPubMedGoogle Scholar
  16. 16.
    Loetscher H, Brockhaus M, Dembic Z et al. (1992) Two distinct human TNF receptors: purification, molecular cloning and expression. In: Osawa T, Bonavida B (eds): Tumor necrosis factor: structure-funcion, relationship and clinical application. Karger, Basel, pp 34–46Google Scholar
  17. 17.
    Mease PJ, Goffe BS, Metz J et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385–390PubMedGoogle Scholar
  18. 18.
    Mease P, Kivitz A, Burch F et al. (2001) Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial. Arthritis Rheum 44 [Suppl]:S90–A226Google Scholar
  19. 19.
    Wyeth (2003) Moderne Rheumatherapie. Patienteninformation. Wyeth Europa Ltd. Berkshire, p 31Google Scholar
  20. 20.
    Mohler KM, Torrance DS, Smith CA et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561PubMedGoogle Scholar
  21. 21.
    Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-α therapies: the next generation. Nat Rev Drug Discover 2:736–746CrossRefGoogle Scholar
  22. 22.
    Papp KA, Tyring S, Lahfa M et al. (2005) A global phase III randomized controlled trial of etanercept in psoriasis; safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304–1312PubMedGoogle Scholar
  23. 23.
    Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483–1489CrossRefPubMedGoogle Scholar
  24. 24.
    Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17–21CrossRefPubMedGoogle Scholar
  25. 25.
    Rott S, Mrowietz U (2005) Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. Br Med J 330:716–720Google Scholar
  26. 26.
    Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 [Suppl 2]:51–53Google Scholar
  27. 27.
    Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194–199CrossRefPubMedGoogle Scholar
  28. 28.
    Schottelius AJG, Moldawer LL, Dinarello CA et al. (2004) Biology of tumor necrosis factor-α-implications for psoriasis. Exp Dermatol 13:193–222CrossRefPubMedGoogle Scholar
  29. 29.
    Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579–580CrossRefPubMedGoogle Scholar
  30. 30.
    Stone JH, Uhlfelder ML, Hellmann DB et al. (2001) Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-months open-label trial to evaluate safety. Arthritis Rheum 44:1149–1154CrossRefPubMedGoogle Scholar
  31. 31.
    Weinberg JM (2004) Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. J Am Acad Dermatol 50:P143CrossRefGoogle Scholar
  32. 32.
    Wozel G (Hrsg) (2004) UNI-MED Verlag AG. Bremen London BostonGoogle Scholar
  33. 33.
    Wozel G (2005) Clinical review: psoriasis. Recent advances in the treatment of psoriasis. Hospital Pharmacy Europe, London, Sept./Oct. 2005:1–3Google Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Custav Carus Dresden an der Technischen Universität Dresden
  2. 2.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität DresdenDresden

Personalised recommendations